Posted in Clinical Data Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls April 21, 2026 BioSpace The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer. Clinical DataOncologyRead full story